 |
|
Molecular 'on/off switch' controls immune defenses against viruses
December 26, 2006Much like flipping a light switch, the hepatitis C virus turns on human immune defenses upon entering the body but also turns off those defenses by manipulating interaction of key cellular proteins, UT Southwestern Medical Center researchers have found.
This same molecular "on/off switch" controls immunity against many viruses, highlighting a potential new target for novel therapeutics to fight viruses, the researchers report.
In a study available online this week and in an upcoming issue of the Proceedings of the National Academy of Sciences, UT Southwestern scientists describe how the proteins RIG-I and LGP2 normally interact to turn on and off immune response to hepatitis C.
It's known that when a virus invades a cell, the RIG-I protein triggers the body to generate an immune response. Once the virus has been cleared out, the LGP2 protein turns off the RIG-I signals.
This interaction between RIG-I and LGP2 is vital for properly regulating immunity, but viruses such as hepatitis C can disrupt the normal process to shut down immune defenses early, the research team found.
"This knowledge will help us design drugs that mimic the viral effects on these proteins to either activate a host's immune response or shut it down," said Dr. Michael Gale, associate professor of microbiology and the study's senior author. "This holds great potential in developing new disease therapies, because the tactics employed by hepatitis C to trigger immune response are similar to those employed by other viruses such as West Nile, influenza and the common cold."
Dr. Gale's research centers on studying the mechanisms viruses use to evade immune defenses. Of particular interest is the hepatitis C virus, a blood-borne infection transmitted by intravenous drug use, blood transfusions and sexual contact. It affects 4 million U.S. residents and is the nation's leading cause of cirrhosis and liver cancer.
In 2005 Dr. Gale and his team completed several breakthrough studies on hepatitis C, discovering that the RIG-I protein binds to viral genetic material. Then, RIG-I changes its shape and sends signals to other proteins that spur production of interferon, a molecule that stops viral replication. The researchers also found that the virus launches a counterattack on RIG-I, producing a protein called a protease to disrupt the signaling process, preventing interferon production and allowing viral replication.
Just how RIG-I signaling is normally regulated, however, hadn't been known.
In the current study, UT Southwestern researchers found that RIG-I and LGP2 each contain a repressor domain, a sort of docking site that controls the actions of each protein. The domain is the key site that regulates the ability of RIG-I to bind to its signaling partners, including LGP2, acting as a switch for controlling immune response, Dr. Gale said.
"Hepatitis C and others viruses hijack this signaling pathway to stop immune defenses," he said.
His research team and others are working to design novel therapeutics and drugs that could mimic viral effects on RIG-I to spur antiviral response or, conversely, mimic viral effects on LGP2 to shut down RIG-I activity. RIG-I shutdown would be necessary in cases when the immune system's response to a virus is dangerously overactive, which happened in many flu cases during the 1918 pandemic.
"Fine-tuning immune response to infection is where antiviral or immune regulatory drugs are headed," said Dr. Gale.
UT Southwestern Medical Center
It's known that when a virus invades a cell, the RIG-I protein triggers the body to generate an immune response. Once the virus has been cleared out, the LGP2 protein turns off the RIG-I signals.
This interaction between RIG-I and LGP2 is vital for properly regulating immunity, but viruses such as hepatitis C can disrupt the normal process to shut down immune defenses early, the research team found.
"This knowledge will help us design drugs that mimic the viral effects on these proteins to either activate a host's immune response or shut it down," said Dr. Michael Gale, associate professor of microbiology and the study's senior author. "This holds great potential in developing new disease therapies, because the tactics employed by hepatitis C to trigger immune response are similar to those employed by other viruses such as West Nile, influenza and the common cold."
Dr. Gale's research centers on studying the mechanisms viruses use to evade immune defenses. Of particular interest is the hepatitis C virus, a blood-borne infection transmitted by intravenous drug use, blood transfusions and sexual contact. It affects 4 million U.S. residents and is the nation's leading cause of cirrhosis and liver cancer.
In 2005 Dr. Gale and his team completed several breakthrough studies on hepatitis C, discovering that the RIG-I protein binds to viral genetic material. Then, RIG-I changes its shape and sends signals to other proteins that spur production of interferon, a molecule that stops viral replication. The researchers also found that the virus launches a counterattack on RIG-I, producing a protein called a protease to disrupt the signaling process, preventing interferon production and allowing viral replication.
Just how RIG-I signaling is normally regulated, however, hadn't been known.
In the current study, UT Southwestern researchers found that RIG-I and LGP2 each contain a repressor domain, a sort of docking site that controls the actions of each protein. The domain is the key site that regulates the ability of RIG-I to bind to its signaling partners, including LGP2, acting as a switch for controlling immune response, Dr. Gale said.
"Hepatitis C and others viruses hijack this signaling pathway to stop immune defenses," he said.
His research team and others are working to design novel therapeutics and drugs that could mimic viral effects on RIG-I to spur antiviral response or, conversely, mimic viral effects on LGP2 to shut down RIG-I activity. RIG-I shutdown would be necessary in cases when the immune system's response to a virus is dangerously overactive, which happened in many flu cases during the 1918 pandemic.
"Fine-tuning immune response to infection is where antiviral or immune regulatory drugs are headed," said Dr. Gale.
UT Southwestern Medical Center
Immune Response Current Events and Immune Response News RSSLung cancer cells activate inflammation to induce metastasis
A research team from the University of California, San Diego School of Medicine has identified a protein produced by cancerous lung epithelial cells that enhances metastasis by stimulating the activity of inflammatory cells.
Researchers engineer pancreatic cell transplants to evade immune response
In a finding that could significantly influence the way type 1 diabetes is treated, researchers at Albert Einstein College of Medicine of Yeshiva University have developed a technique for transplanting insulin-producing pancreatic cells that causes only a minimal immune response in recipients.
Scientists Identify New Congenital Neutropenia Syndrome and Causative Gene Mutation
A team of scientists has discovered a new syndrome associated with severe congenital neutropenia (SCN), a rare disorder in which children lack sufficient infection-fighting white cells, and identified the genetic cause of the syndrome: mutations in the gene Glucose-6-phosphatase, catalytic subunit 3 (G6PC3).
New genetic markers for ulcerative colitis identified, researchers report in Nature Genetics
An international team led by University of Pittsburgh School of Medicine researchers has identified genetic markers associated with risk for ulcerative colitis.
Cancer drug effectively treats transplant rejections
University of Cincinnati (UC) researchers have discovered a new therapy for transplant patients, targeting the antibody-producing plasma cells that can cause organ rejection.
May hepatic granulomas be part of the histological spectrum of chronic hepatitis C?
While older large series of patients with hepatic granulomas have found sarcoidosis and tuberculosis to be the most common causes of hepatic granulomas, recent works have noted some patients with chronic hepatic C and hepatic granulomas and no other obvious associations.
Researchers identify new anti-tumor gene
Researchers from Virginia Commonwealth University have identified a new anti-tumor gene called SARI that can interact with and suppress a key protein that is overexpressed in 90 percent of human cancers. The discovery could one day lead to an effective gene therapy for cancer.
Mathematical models of adaptive immunity
More than five million people die every year from infectious diseases, despite the availability of numerous antibiotics and vaccines.
Study first to show that RNA interference can facilitate vaccine development
Pharmaceutical companies and universities are racing to develop drugs that use the gene silencing mechanism known as RNA interference to treat a host of diseases.
Scans show immune cells intercepting parasites
Researchers may have identified one of the body's earliest responses to a group of parasites that causes illness in developing nations.
More Immune Response Current Events and Immune Response News Articles
 | Primer to The Immune Response by Tak W. Mak, Mary Saunders Primer to The Immune Response is an invaluable resource for college students, university undergraduates and students in medicine and other health professions who need a concise but complete and understandable introduction to immunology.This book is written in the same engaging conversational style as the published reference book The Immune Response: Basic and Clinical Principles and conveys the... |
 | Immunity: The Immune Response to Infectious and Inflammatory Disease (Primers in Biology) by Anthony DeFranco, Richard Locksley, Miranda Robertson An understanding of the immune system is central to the understanding of how the body interacts with its surroundings, and how it both protects itself and responds to infectious disease. But what processes underpin the body's response to infection? How does our immune system remember its previous encounters? And what happens when the tight regulation of the immune system fails? Immunity:... |
 | Five Star Science Fiction/Fantasy - Immune Response by Steve Perry A New York Times Bestselling Author In the deep woods of the Pacific Northwest, things aren't quite what they seem . . . Physician's Assistant Rick Scales has a quiet practice at the end of the road, near the Makah Indian Reservation, in Neah Bay, Washington. But amidst the Douglas fir along Puget Sound, Scales has come across a problem: his patients aren't dying the way they should. When a... |
 | Immune Response in the Criticaly Ill (Update in Intensive Care and Emergency Medicine) This book brings together basic scientists or clinicians from a variety of different backgrounds - immunology, infectious diseases or critical care - who share a common interest in understanding the changes that occur in immune responses in sepsis. It provides an up to date and unrivalled synthesis of current research in this rapidly developing... |
 | The Innate Immune Response to Infection |
| Cancer Surveys Volume 22 Molecular Mechanisms of the Immune Response by W.F. and M.J. Owen editors Bodmer | |
| Regulation of the Immune Response | |
| Local Immune Responses of the Gut by Newby/StokeS | |
| Molecular Aspects of Immune Response and Infectious Diseases (Advances in Host Defense Mechanisms) by H. Kiyono, E. Jirillo, C. Desimone | |
 | West Nile Encephalitis Virus Infection: Viral Pathogenesis and the Host Immune Response (Emerging Infectious Diseases of the 21st Century) West Nile virus is a neurotropic flavivirus that has emerged globally as a significant cause of viral encephalitis in humans. Infection of humans is associated with a febrile illness that can progress to meningitis and encephalitis with symptoms including cognitive dysfunction and flaccid paralysis. Following its introduction to the United States in 1999, West Nile virus rapidly disseminated... |
| © 2009 BrightSurf.com |